This article has been updated from a previous version
NEW YORK, Jan 24 - Agilent has licensed its custom in situ DNA microarrays to Applied Biosystems under a technology access agreement, the companies said Wednesday.
Applied Biosystems will use the microarrays for internal research and development only and did not gain a license to commercialize the Agilent arrays.
The parties did not disclose the financial terms of the agreement, and Agilent technologies declined to comment on details, citing a contractual arrangement with ABI.
“This deal is not going to be discussed,” said Agilent spokesman Doug Forsyth.
Applied Biosystems' comments were similarly succinct. " The agreement allows us to purchase affordable custom in situ synthesized oligonucleotide microarrays instead of manufacturing them in-house," said Applied Biosystems spokesman Jay Rhodes.
Since Agilent shipped its first large batch of custom DNA microarrays in September to Rosetta Inpharmatics, it has also signed deals to provide microarray s to DiaDexus, Paradigm Genetics, and Exelixis. Agilent distributes the Rosetta Resolver.
Earlier this month, Agilent licensed Incyte’s cDNA clone sets so it could make animal and human gene expression microarrays. Researchers using these arrays will have click-through access to Incyte’s LifeSeq gene-by-gene site so they can purchase additional information on specific genes.
Applied Biosystems said it is also continuing to develop systems for multiplexed DNA analysis through collaborations with 3M, Aclara BioSciences, Hyseq, and Illumina.